Références : 1. Monographie de Jivi, Bayer Inc., 20 mai 2024. 2. Coyle TE, et al. Phase I study of BAY 94-9027, a PEGylated B-domain-deleted recombinant factor VIII with an extended half-life, in subjects with hemophilia A. J Thromb Haemost 2014;12:488–96. 3. Ivens IA, et al. PEGylated therapeutic proteins for haemophilia treatment: a review for haemophilia caregivers. Haemophilia 2013;19:11–20. 4. Mei B, et al. Rational design of a fully active, long-acting PEGylated factor VIII for hemophilia A treatment. Blood 2010;116:270–9. 5. Données internes. CSR PH-36909, Bayer Inc., 21 mars 2013. 6. Reding MT, et al. Safety and efficacy of BAY 94-9027, a prolonged-half-life factor VIII. J Thromb Haemost 2017;15:411–9. 7. Church N, et al. Factor VIII activity of BAY 94-9027 is accurately measured with most commonly used assays: Results from an international laboratory study. Haemophilia 2018;24:823–32.